
ADiTx Therapeutics ADTX
$ 0.43
-9.52%
Quarterly report 2025-Q2
added 08-14-2025
ADiTx Therapeutics Interest Expense 2011-2026 | ADTX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense ADiTx Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 5.84 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.84 K | 5.84 K | 5.84 K |
Quarterly Interest Expense ADiTx Therapeutics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 740 K | 70.8 K | - | - | 15.8 K | - | - | - | 5.84 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 740 K | 5.84 K | 208 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
AbCellera Biologics
ABCL
|
-2.71 M | $ 3.55 | -2.18 % | $ 1.06 B | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
ADMA Biologics
ADMA
|
-212 K | $ 15.66 | -5.32 % | $ 3.73 B | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
-133 K | $ 20.16 | 1.51 % | $ 2.54 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
-4.03 M | $ 75.5 | -1.35 % | $ 1.46 B | ||
|
Applied Therapeutics
APLT
|
-27 K | - | - | $ 8.42 M | ||
|
Autolus Therapeutics plc
AUTL
|
9.29 M | $ 1.48 | -9.2 % | $ 378 M | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Athersys
ATHX
|
103 K | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
3.39 M | $ 7.8 | -7.36 % | $ 33.8 M | ||
|
CorMedix
CRMD
|
34.3 K | $ 6.32 | -11.24 % | $ 322 M | ||
|
AVEO Pharmaceuticals
AVEO
|
1.6 M | - | - | $ 521 M | ||
|
Champions Oncology
CSBR
|
73 K | $ 5.79 | -3.58 % | $ 79.1 M | ||
|
Axsome Therapeutics
AXSM
|
-15.9 M | $ 160.44 | -2.22 % | $ 7.98 B | ||
|
BridgeBio Pharma
BBIO
|
43.1 M | $ 65.38 | -1.74 % | $ 12.5 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-93 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B | ||
|
Equillium
EQ
|
-76 K | $ 1.79 | 2.0 % | $ 62.2 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
2.66 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | ||
|
BioLineRx Ltd.
BLRX
|
9.07 M | $ 2.75 | -2.14 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
15.3 M | $ 60.47 | 0.07 % | $ 11.6 B | ||
|
Eton Pharmaceuticals
ETON
|
1.06 M | $ 17.04 | -2.77 % | $ 437 M |